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Context: Streptococcus pneumoniae [pneumococcus] induces a large 
variety of the diseases burden such as bacteremia, meningitis, otitis media 
and pneumonia in human. Among these, the meningitis can be disclosed 
with long-lost diseases sequelae. Over the last decades, various 
recommendations and consensus were released to better manage this major 
respiratory disease.  
 Evidence Acquisition: However, there is a controversy among the 
clinicians about the best strategy in dealing with this chronic infection. In 
brief, using proper antibiotics or conjugate vaccine to battle this bacterium is 
a critical question for the clinical setting.  
Results: Taken together, it seems that the best possible adopted strategy is 
to apply the pneumococcal conjugate vaccines in management due to the 
following two reasons: 1) reducing the bacterial antibiotic resistance rates 
and 2) decreasing the prevalence of pneumoniae mortality and morbidity at 
global scale 
Conclusion: Conclusively, continuous surveillance surveys determining 
antibiotic resistance seem inevitable to track pneumococcal genetical 
variable populations for both successful antibiotic therapy and proper 
vaccination. 
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     Following the isolation of Streptococcus 
pneumonia [S. pneumonia] in 1881’s by 
Louis Pasteur, it seems necessary to observe 
this bacterium as listed among the bacteria 
with yet hundreds of unanswered questions. 
This encapsulated gram-positive diplococci 
are genetically and phenotypically close to 
various species of streptococci habituated in 
the human oral cavity [1]. Notably, the 
colonization with this bacterium in the 
upper respiratory system stays 
asymptomatic in many of the colonized 
individuals [2]. Clinically, this facultative 
microbe is responsible for invasive and non-
invasive diseases, ranging from mild ones 
including simple sinusitis to more severe 
diseases including septicemia and 
meningitis [3, 4]. The S. pneumonia is a 
bacterium that basically remains commensal 
in the human nasopharynx; nonetheless, in a 
certain situations, it becomes pathogen and 
finally causes severe diseases such as 
meningitis and pneumonia with relatively 
higher mortality rates [5, 6].  S. pneumonia 
is estimated to be solely responsible for 
35% of all kind of pneumonia [7]. Only in 
the developing countries, S. pneumoniae is 
a main causative agent of more than one 
million death after meningitis and sinusitis 
among children [8]. As already mentioned, 
there are still large amount of unknown 
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queries about this bacterium, listed as 
virulence factors and the pattern of 
antibiotic resistance. Nowadays, it is widely 
debated and some have agreed that strain-
dependent capsule is an unforgettable 
virulence factor detected in this microbe [9, 
10]. The capsule efficiently helps the 
pneumococcus to persist while facing active 
phagocytosis by immune cells, mainly 
alveolar macrophages [11]. S. pneumonia 
has been known as  a dangerous infectious 
agent for children under 3 years old and 
also the most controllable bacteria by the 
vaccine for many years [12]. Morbidity and 
mortality reported by the colonization of S. 
pneumonia were sharply increased in recent 
years due to the i) emergence of antibiotic 
resistance, ii) lack of an ideal vaccine 
against all clinical strains, iii) increased 
aged patients with chronic illness and iv) 
hospitalization [13-15]. To now, there has 
been two main tools in battle with this 
persistent microorganism: antibiotic therapy 
and vaccination [16]. In brief, there is no 
clear determined strategy for how to deal 
with this infection in various patients. In 
this review, the main purpose was to 
address two items affecting the low success 
rate in the management of S. pneumonia 
infections. Moreover, likely prospective of 
this infection was concentrated on.   
 
2. Evidence Acquisition 
2.1 Antibiotics 
     As expected, antibiotics were applied to 
eradicate the S. pneumonia isolating from 
clinical samples while the emergence of 
resistance hampered successful treatment of 
this bacterium [17, 18]. Regarding bacterial 
populations, applying inappropriate 
antibiotics formula resulted in failed therapy 
and selection of resistant/persistent bacterial 
clones [antibiotic selection pressure].  
Pneumococcal strains are usually exposed 
to the prescribed antibiotics available in the 
nasopharynx and mostly propagate in 
mucosal microniche [19-21]. Among the all 
gram positive and negative microorganisms, 
pneumococcus is highly potent to receive 
the new DNA using the transformation 
approach [22]. This DNA update helped the 
pneumococcus to survive regardless of the 
environmental antibiotics existence; thus, 
new offsprings emerged rapidly causing the 
epidemic pneumoniae among both adults 
and infants [23, 24]. The problem with 
streptococci is that human nasopharynx can 
be an immense territory for commensal 
bacteria carrying the resistant elements with 
potency of transforming to the 
pneumococcus. In 1912, Optochin 
resistance was reported from experimental 
assays, being an alarming sound for clinical 
practice concerning difficulty in treating 
this bacterium in close future [25]. During 
the 1935s and 1940s, patients with 
meningitis caused by S. pneumonia showed 
high resistance rate into the sulfonamide 
[26]. Interestingly, occurrence of resistance 
to the penicillins lasted until 1968s as 
reported [27]. Later, resistance to the 
chloramphenicol was found among the 
clinical isolates while tetracycline 
susceptibility rates were also reduced in 
many of geographical regions [28, 29]. 
Broadly defined, multidrug-resistant [MDR] 
pneumococci are characterized by 
resistance to 3 or more antibiotics at the 
same time. Although MDR isolates were 
firstly defined among the pediatric cases, 
later other research groups were able to 
identify these classes of antibiotic-resistant 
strains from the adult groups [30-33]. 
Reports on antibiotic resistance of S. 
pneumonia to the macrolides have 
increasingly come into the media and 
scientific communities. Since S. 
pneumoniae is the first ranked bacterium 
among causative agents of community-
acquired pneumonia, an efficient antibiotic 
therapy would be preferable by clinicians. 
To date, the macrolides are the first and 
most effective choice in elimination of this 
bacterium in colonized hosts. On the other 
side, current evidence manifesting the rate 
of macrolides resistance is getting close to 
alarming levels in global scale. Previous 
inappropriate usages of macrolide is the 
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main risk factor escalating the trend of 
failed therapy using this antibiotics against 
S. pneumonia. As such, better prescription 
policies in clinics and increased awareness 
of patients about the threats of the 
uncontrolled drug consumptions will be the 
main solution in this unfair war! Relatively 
high rate of resistance among the clinical 
strains of S. pneumonia to the 
cephalosporins and macrolides is a critical 
concern which needs intensive attention to 
have better insight into diseases-associated 
statics about this respiratory system 
bacterium [19, 20, 34-38]. 
 
3. Results 
     The important rationale for using the 
vaccine against S. pneumonia infection are 
as follows:               i)  large burden of aged 
population in the world, ii) increased health 
status after proper vaccinations, and iii) lack 
of proper antibiotic therapy in clinical 
practice. Having capsular based design is a 
pitfall for general dissemination of this 
application among the candidates. From the 
beginning, pneumococcal conjugated 
vaccines [PCV] were designed to reduce the 
prevalence of this persistent bacterium, but 
rapid emergence of different circulating 
serotypes led to the defeated vaccines 
projects worldwide [39-42]. Another basic 
problem was the decreased immunogenic 
response to the polysaccharides 
composition of PCV among the young 
individuals and also infants. Since twenty 
years ago, certain proteins were conjugated 
into the available vaccine, thus T-cell 
mediated immunity was initiated 
subsequently [43-45]. The main concern is 
that despite wide spread usage of PCV, 
pneumococcal-associated death rate is still 
increasing, according to the recent WHO 
released news [46]. In 2014, Tabatabaei et 
al reported that limited success rate of PCV 
13, mainly among the young population, is 
a major threat for public health in Iran. 
However this finding is contradictory and 
confirmatory in comparison with different 
groups [47-50]. Although the status for Iran 
is quite different, in Japan, the [PCV-7] they 
announced recommendations for volunteers 
in order to increase the hygiene situation. In 
total, introducing the seven-valents PCV 
[14, 18C, 23F, 19F, 6B, 4 and 9V] 
conjugate vaccines, which was a main cause 
of reduced incidence of pneumococcal 
associated diseases worldwide, was the 
main cause of the emergence of non-
vaccine serotypes of S. pneumonia. For 
example, 19A was a dominant non-vaccine 
strain which caused pneumonia with high 
rate of antibiotic resistance [mostly MDR-
strains] at national and international levels 
[51-54]. Moreover, 19A was recently 
emerged as a dominant serotype with 
antibiotic resistance among the patients with 
invasive diseases [55, 56]. A large body of 
evidence indicate that the universal spread 
of 19A is a major clinical issue and it needs 
further attentions, especially in developing 
and low income countries. Pneumococcus is 
considered to be the first rank agent in 
pneumonia acquired from the community in 
comparison with other human respiratory 
pathogens. Not only because of failures in 
establishment of routine antibiotics 
susceptibility tests in clinical settings, but 
also for inconsistent national programs, 
there is no clear guideline to address this 
problematic and killing diseases, especially 
for children under 2-4 years old, mainly in 
developing countries.  Although it is more 
than a century that the scientists have 
knowledge about the S. pneumonia, still the 
questions exist about how to manage this 
infection among the patients especially high 
risk individuals. It is frequently stated that 
nasopharyngeal carriage of pneumococcal 
isolates is the main route of transmission 
into new hosts [57-59]. Therefore, 
determining the circulating serotypes 
among the vaccine-target persons would be 
a novel strategy before starting the 
vaccination projects, particularly in 
developing and low-income countries. 
Presently, most of attempts to produce a 
preventive vaccine were devoted to suggest 
a conjugate vaccine; and yet in reality, 
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pneumococcal diseases, mainly with 
invasive prognosis, pose huge death rates 
worldwide. The first available idea is to 
shift in strategy to produce a vaccine from 
conjugate to the novel alternative ones. 
Using the proteins in combination with 
selective bacterial antigen is a new era 
which may answer today’s frequent queries 
in the management of pneumococcal-
associated diseases. Last but not least, 
continuous follow-up programs about 
antibiotic resistance are necessary to track 
pneumococcal genetical variable 
populations for both a successful antibiotic 




     The antibiotic resistance of S. 
pneumoniae has become a major public 
health dilemma, even for developed 
countries. In this line, countries such as the 
United States reported that the prevalence 
of drug-resistant strains has increased and in 
response with this problem, different 
strategies to compensate are required.  
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